HK1040637B - Igf/igfbp的藥用製劑 - Google Patents

Igf/igfbp的藥用製劑

Info

Publication number
HK1040637B
HK1040637B HK02102400.8A HK02102400A HK1040637B HK 1040637 B HK1040637 B HK 1040637B HK 02102400 A HK02102400 A HK 02102400A HK 1040637 B HK1040637 B HK 1040637B
Authority
HK
Hong Kong
Prior art keywords
igfbp
igf
pharmaceutical formulations
complex
disclosed
Prior art date
Application number
HK02102400.8A
Other languages
English (en)
Other versions
HK1040637A1 (en
Inventor
Danko Stephen
Passmore David
Ogawa Yasushi
Original Assignee
謝爾特里克斯葯品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 謝爾特里克斯葯品公司 filed Critical 謝爾特里克斯葯品公司
Publication of HK1040637A1 publication Critical patent/HK1040637A1/xx
Publication of HK1040637B publication Critical patent/HK1040637B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK02102400.8A 1998-06-01 2002-03-28 Igf/igfbp的藥用製劑 HK1040637B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (2)

Publication Number Publication Date
HK1040637A1 HK1040637A1 (en) 2002-06-21
HK1040637B true HK1040637B (zh) 2006-01-06

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102400.8A HK1040637B (zh) 1998-06-01 2002-03-28 Igf/igfbp的藥用製劑

Country Status (14)

Country Link
US (2) US6436897B2 (zh)
EP (1) EP1082133B1 (zh)
JP (1) JP2002516871A (zh)
KR (1) KR20010052500A (zh)
CN (1) CN1201816C (zh)
AT (1) ATE270898T1 (zh)
AU (1) AU4326799A (zh)
BR (1) BR9910863A (zh)
CA (1) CA2330925C (zh)
DE (1) DE69918690T2 (zh)
ES (1) ES2221456T3 (zh)
HK (1) HK1040637B (zh)
IL (1) IL139969A0 (zh)
WO (1) WO1999062536A2 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
AU2005277357B2 (en) 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
ATE459637T1 (de) * 2004-12-24 2010-03-15 Insmed Inc Gereinigte rhigf-i/rhigfbp-3-komplexe und herstellungsverfahren dafür
RU2442822C2 (ru) * 2005-01-25 2012-02-20 Вайет Рисерч Айрлэнд Лимитед Вещества, защищающие клетки от рассечения при сборе микрофильтрацией
PL1861116T3 (pl) * 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
AU2007291501B2 (en) 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
WO2010096125A1 (en) * 2008-10-29 2010-08-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
NZ600454A (en) 2009-11-30 2014-10-31 Univ Queensland Fibronectin: growth factor chimeras
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2013116847A1 (en) * 2012-02-03 2013-08-08 Charm Sciences, Inc. Extraction of mycotoxins
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
WO2016209773A1 (en) * 2015-06-22 2016-12-29 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CA3007276C (en) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
WO2017117236A1 (en) * 2015-12-31 2017-07-06 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
EP3522867A1 (en) 2016-10-07 2019-08-14 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
CA3194764A1 (en) * 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
EP0726911B1 (en) 1993-09-20 2002-10-30 Celtrix Pharmaceuticals, Inc. Treatment of hematologic disorders with a igf-1/igfbp-3 complex
JPH09509140A (ja) 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
EP0732933B1 (en) * 1993-11-15 2002-10-09 Celtrix Pharmaceuticals, Inc. Use of igf-1 and igfbp-3 in the manufacture of a medicament for treating a renal disorder
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
US20030087806A1 (en) 2003-05-08
WO1999062536A2 (en) 1999-12-09
ES2221456T3 (es) 2004-12-16
WO1999062536A3 (en) 2000-03-30
EP1082133A2 (en) 2001-03-14
US20020004478A1 (en) 2002-01-10
EP1082133B1 (en) 2004-07-14
DE69918690T2 (de) 2005-08-18
CN1201816C (zh) 2005-05-18
JP2002516871A (ja) 2002-06-11
CA2330925A1 (en) 1999-12-09
CA2330925C (en) 2010-02-09
KR20010052500A (ko) 2001-06-25
IL139969A0 (en) 2002-02-10
BR9910863A (pt) 2002-06-11
HK1040637A1 (en) 2002-06-21
AU4326799A (en) 1999-12-20
ATE270898T1 (de) 2004-07-15
US6436897B2 (en) 2002-08-20
CN1315868A (zh) 2001-10-03
DE69918690D1 (de) 2004-08-19

Similar Documents

Publication Publication Date Title
HK1040637B (zh) Igf/igfbp的藥用製劑
IL140710A0 (en) Pulmonary delivery of active agents
CA2148537A1 (en) Stable freeze-dried formulation comprising a protein; assay kit
DK1141015T3 (da) Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
FI960750A0 (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
DE69834251D1 (de) gefrorenes Dessert, welches Milchsäurebakterien und fermentierbare Ballaststoffe enthält
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
IL133053A0 (en) Local delivery of long lasting therapeutic agents
EP0276543A3 (en) Use of buspirone for the improvement of short term memory
DE69004004D1 (de) Kolloidales Fluorid und orale Zusammensetzung.
MY116421A (en) New formulation
ZA991482B (en) Lipopeptide antibiotic calcium salts, process for their preparations, and their use.
GR3034309T3 (en) IFN--g(b) LIQUID FORMULATIONS
SE9402880D0 (sv) New peptide derivatives
SE9604795D0 (sv) New pharmaceutical formulation
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
IL141850A0 (en) HIGH PURITY COMPOSITION COMPRISING (7α,17alpha;)- 17-HYDROXY- 7-METHYL-19-NOR -17 -PREGN-5(10)-EN-20-YN-3-ONE
ES2142249A1 (es) Esmalte ceramico bactericida y sus aplicaciones.
JO1992B1 (en) Fixed pharmaceutical compounds based on the derivatives of quinpristine and dalphopristine materials and their preparation process
ZA966577B (en) Pharmaceutical composition.
NO20006022L (no) Rekombinant human interferon <beta>-1A (IFN-<beta>-1A)- formulering
ZA953584B (en) Novel active peptide and its preparation
AU4984899A (en) Nutritionally active composition for hardening fingernails
孙绪生 et al. EskoLansimies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110528